



SC1: SME instrument Fast Track to Innovation InnovFin



SC1 NCP meeting – 30 April 2015

**Antoine Mialhe
DG Research & Innovation – Health Directorate
European Commission**

antoine.mialhe@ec.europa.eu

SME instrument: 3 phases

SME instrument in:
• H2020: ~ €3 billion
• SC1 Health: ~ €500 million

Idea



Phase 1

Feasibility Assessment

- Feasibility of concept
- Risk assessment
- IP regime
- Partner search
- Design study

€50,000
~ 6 months

Phase 2

Innovation / R&D project

- Clinical trials
- Development, prototyping, scaling-up
- Miniaturisation, design
- Market validation
- Etc.

€1 to 5 million
~36 months
100% funding rate in SC1

Phase 3

Commercialisation

- Facilitate access to private finance
- Support via networking, training, coaching, knowledge sharing, dissemination

No direct funding

Market



SME instrument features

One topic in SC1 Health for 2014/2015:

- **PHC-12:** Clinical research for the validation of biomarkers and/or diagnostic medical devices

Overall budget for 2014/15: €111 million

In 2014: 3 cut-offs in phase 1, 2 in phase 2

In 2015: 4 cut-offs in phase 1 & 2; 3 upcoming:

- 17/06/2015 ; 17/09/2015 ; 25/11/2015
- Open PHC-12 phase 2 in 2016 for the last successful phase 1 of 2015

PHC-12: Phase 1

2014

1st cut-off - 18 June

- 208 proposals submitted
- 24 above thresholds – all funded
- Success rate: **11,5%**

2nd cut-off - 24 September

- 152 proposals submitted
- 21 above thresholds – all funded
- Success rate: **13,8%**

3rd cut-off - 17 December

- 195 proposals submitted
- 32 above thresholds – all funded
- Success rate: **16,4%**

2015

4th cut-off – 18 March

- 105 proposals submitted
- Evaluations on-going

Funded SMEs per country – phase 1

Country	1 st cut-off 18 June	2 nd cut-off 24 September	3 rd cut-off 17 December	Total
Austria	1	1	2	4
Belgium	-	1	-	1
Germany	2	2	2	6
Denmark	-	1	2	3
Estonia	-	1	-	1
Spain	6	2	4	12
Finland	-	2	1	3
France	2	2	-	4
Hungary	1	-	1	2
Ireland	1	1	1	3
Israel	2	-	-	2
Iceland	-	-	1	1
Italy	-	3	5	8
The Netherlands	1	5	3	9
Norway	-	-	2	2
Serbia	-	1	-	1
Sweden	2	-	2	4
Turkey	1	-	-	1
United Kingdom	6	1	7	14
Total	25*	23*	33*	81*

*The difference with the number of projects funded is due to the fact that some projects have several SMEs

PHC-12: Phase 2

2014

1st cut-off – 9 October

- 81 proposals submitted
- 30 above thresholds
- 10 projects funded
- Average project size: €3,3 m
- Success rate: **12,3%**

2nd cut-off - 17 December

- 91 proposals submitted
- 37 above thresholds
- 9 projects funded
- Average project size: €3,3 m
- Success rate: **10,1%**

2015

3rd cut-off – 18 March

- 90 proposals submitted
- Evaluations on-going

Funded SMEs per country – phase 2

Country	1 st cut-off 9 October	2 nd cut-off 17 December	Total
France	1	1	2
Germany	2	2	4
Greece	-	1	1
Ireland	1	-	1
Italy	-	4	4
Spain	1	-	1
Sweden	-	1	1
The Netherlands	2	2	4
United Kingdom	3	1	4
Total	10	12*	24*

2014 & 2015 overview

2014	Phase 1	Phase 2	Total
Cut-offs	3	2	5
Proposals submitted	505	172	677
Projects funded	77	19	96
SMEs funded	81	24	105
Success rate	15%	11%	14%
Total project EU funding	€3,85 m	€62,5 m	€66,3 m
Average EU funding/project	€50 k	€3,3 m	-
2015	Phase 1	Phase 2	Total
Cut-offs so far	1	1	2
Proposals submitted	105	90	195
Projects funded	Under evaluation		
Remaining cut offs	3	3	6
Remaining EU funding	-	-	€44,6 m

Project examples: phase 1

- Clinical validation of an algorithm to improve the performance a diagnosis pancreatic cancer biomarker
- Clinical validation of a new diagnostic devices screening Methicillin-resistant Staphylococcus aureus (MRSA)
- Development of a real-time in vivo fiber optic-based biomarker sensor device integrated in an existing medical device to improve the protection of babies during birth
- Clinical validation of a software as an imaging biomarker for identifying ischaemic stroke patients

Project examples: phase 2 (1/2)

- Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth
- Validation of a point-of-care H-FABP test for a rapid exclusion of Acute Myocardial Infarction in patients with cardiac complaints.
- Validation of PreCursor-M for enhanced Cervical (Pre) Cancer detection
- Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform
- Validation of clinical performance and pre-commercial development of a novel diagnostic for dental caries assessment

Project examples: phase 2 (2/2)

- Innovative double technologies medical device for corneal diseases
- Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer
- Radiomics of lung cancer (RAIL): non-invasive stratification of tumour heterogeneity for personalised cancer therapy
- Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer's disease
- Validation of blood-brain-barrier permeability as a glioma biomarker

Domains covered so far: phase 2

- Respiratory
- Heart disease: myocardial infarction
- Cancer: cervical, colorectal, pancreatic, bladder, breast, lung (x3)
- Diabete
- Arthritis
- Infections: septic shock
- Infectious diseases : TB, ID self testing platform
- Alzeihmer
- Blood brain barrier permeability
- Corneal disease
- Dental care

Proposals evaluation (1/2)

Scoring:

3 criteria: Excellence / Impact / Implementation

Phase 1 thresholds:

- Excellence: 4/5 ; Impact: 4/5 ; Implementation: 4/5
- Minimum overall threshold: 13/15
- **Score = Excellence + Impact *1,5 + Implementation**

Phase 2 thresholds :

- Excellence: 3/5 ; Impact: 4/5 ; Implementation: 3/5
- Minimum overall threshold: 12/15
- **Score = Excellence + Impact *1,5 + Implementation**

Proposals evaluation (2/2)

Evaluations:

- At least 4 experts review and score each proposal
- Fully remote – no consensus meeting in Brussels
- Final proposal score is the median of experts' scores
- The consensus report comprises a collation of experts' individual reports
- Applicants can provide up to 3 persons that should not act as evaluator


Feedback about evaluations outcome to applicants:

- Phase 1: 2 months after the cut-off date
- Phase 2: 4 months after the cut-off date

Time to contract:

- Phase 1: 1 month after receiving feedback (3 months after cut-off)
- Phase 2: 2 months (6 months after cut-off)

Browse projects funded on EASME website



<http://ec.europa.eu/easme/node/37>

Fast Track to Innovation (FTI)

FTI (2015-16):
€200 million

- **Pilot call: €100 million in 2015 ; €100 million in 2016**
- **Rules & conditions:**
 - Fully bottom-up, close-to-market activities, 70% funding rate
 - Eligibility: 60% of the overall project budget allocated to industry participants in the consortium or majority of industry participants (defined as 'private for-profit organisation')
 - Restricted to MS and AC
 - 3 to 5 partners maximum, max. €3 million EU contribution
 - 3 cut-off dates in 2015: 29 April, 1st September, 1st December
 - End of July: First results of the evaluations

InnovFin Financial instruments

H2020:
~€2.8 billion

- **Instruments covering all type of companies from small to large**
- **How does it work:**
 - Indirect support, improve bankability of companies
 - Provide a guarantee on loans
 - If the company cannot pay back the loan, the bank receive the guarantee which recovers partially the loan
 - Ex: cy X -> project of €300 m, EIB max. loan: €150 m, EC guarantee: €15-30 m
- **InnovFin large projects (with EIB) in 2014:**
 - 9 "Health" cases, 8 received EC bank guarantee
 - Overall 8 projects budget : 1.7 billion euros (≠ than InnovFin budget!)